Clinical Trials
11 trialsNCT02546986 2025-08-08
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Celgene
Phase 2 Completed
NCT02250326 2024-09-19
abound2L+
Celgene
Phase 2 Completed
NCT01928576 2024-05-03
NA_00084192
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT02009436 2020-02-07
Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Albert Einstein College of Medicine
Phase 1 Completed
NCT01478685 2019-11-12
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Celgene
Phase 1 Completed
NCT01545947 2019-11-12
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Celgene
Phase 1 Completed
NCT01281124 2019-09-24
Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00387465 2019-05-09
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01209520 2015-02-24
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
University of Miami
Phase NA Completed
NCT00006019 2013-06-24
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed